Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • KSNM Latest Guidelines...

    KSNM Latest Guidelines for Irritable Bowel Syndrome

    Written by Anjali Nimesh Nimesh Published On 2018-04-23T19:02:31+05:30  |  Updated On 23 April 2018 7:02 PM IST
    KSNM Latest Guidelines for Irritable Bowel Syndrome

    Irritable bowel syndrome (IBS) is a common functional bowel disorder that imposes a considerable burden on health-related quality of life (QOL) worldwide. IBS patients are more likely to suffer from psychiatric diseases, including anxiety and depression, that are healthy individuals.The Korean Society of Neurogastroenterology and Motility (KSNM) published the first version of the medical guidelines for Irritable Bowel Syndrome, IBS in 2005 which was updated a number of time and the present update is the latest one.The primary target population is adult patients diagnosed with or suspected to have, IBS. The major topics are diagnostic modalities, prevention of aggravation, medical treatments, and alternative therapies.



    Clinical Practice Guidelines




    IBS is a chronic, recurrent symptom complex, which includes abdominal pain or discomfort, changes in bowel habit, and bloating for at least 6 months.The final diagnosis of IBS is based on the exclusion of organic diseases that would explain the symptoms and the absence of endoscopic abnormalities. The Rome definition is used both clinically and for research purposes. According to the Rome IV definition, IBS is defined by recurrent abdominal pain on at least 1 day per week on average, for the past 3 months, that is associated with 2 or more of the following symptoms: abdominal pain related to defecation, a change in bowel frequency, and a change in stool form. However, this definition is not always applicable in a clinical setting.

    Key Recommendations


    Colonoscopy


    1. Colonoscopy may be considered in patients with alarm symptoms, eg, rectal bleeding, unexplained weight loss, change in bowel habits persisting after age 50 years, or a family history of bowel cancer.Grade B


    Diet


    2. A low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet, which restricts dietary short-chain carbohydrates, is effective in reducing the symptoms of irritable bowel syndrome.Grade 2C


    Physical Activity


    3. Physical activity may be helpful in improving the symptoms of irritable bowel syndrome.Grade 2C


    Bulking Agents


    4. Bulking agents can provide overall symptom relief in irritable bowel syndrome patients.Bulking agents are fiber supplements, such as psyllium (ispaghula husks), calcium polycarbophil, methylcellulose, and bran.2B


    Osmotic Laxatives


    5. Osmotic laxatives can increase stool frequency in constipation-dominant irritable bowel syndrome patients.Osmotic laxatives are poorly absorbed by the gut and induce water secretion into the intestinal lumen, which softens and eases passage of the stool. Osmotic agents, such as polyethylene glycol (PEG), lactulose, sorbitol, and magnesium hydroxide, are inexpensive and have been validated in RCTs for chronic constipation.2B


    Antispasmodic Agents


    6. Antispasmodics are effective in treating abdominal discomfort and pain in irritable bowel syndrome patients.Antispasmodics, including smooth muscle relaxants, anti-muscarinic agents, anticholinergics, and calcium channel blockers, have long been used to treat IBS.1B


    Anti-diarrheal Agents


    7. Loperamide is recommended to improve stool consistency and decrease bowel frequency in diarrhea-dominant irritable bowel syndrome patients. Loperamide is a synthetic opioid receptor agonist that stimulates inhibitory presynaptic receptors in the enteric nervous system, resulting in inhibition of peristalsis and secretion. Loperamide is the most commonly used drug for multiple symptoms of IBS, particularly diarrhea.1C


    Serotonin Subtype 3 Receptor Antagonists


    8. Ramosetron, a serotonin subtype 3 receptor antagonist, improves stool consistency, abdominal pain/bloating, and health-related quality of life in diarrhoea-dominant irritable bowel syndrome patients. 2A



    Serotonin Subtype 4 Receptor Agonists


    9.Prucalopride, a serotonin subtype 4 receptor agonist, may improve stool consistency, abdominal pain/bloating, and health-related quality of life in constipation-dominant irritable bowel syndrome patients whose bowel symptoms are refractory to simple laxatives. 2C



    Antibiotics


    10. Rifaximin may be effective in reducing global symptoms of diarrhea-dominant irritable bowel syndrome.Rifaximin is a poorly absorbable rifamycin derivative that inhibits bacterial transcription.2B


    Probiotics


    11. Statement: Probiotics may be considered to relieve global symptoms, bloating, and flatulence in irritable bowel syndrome patients.Probiotics improve mucosal integrity and restore the intestinal barrier by regulating the gut microbiota.


    Antidepressants


    12. Tricyclic antidepressants may be considered in patients with irritable bowel syndrome for abdominal pain relief and global symptom improvement.Tricyclic antidepressants (TCAs) can be considered in IBS patients whose symptoms are not improved by laxatives, loperamide, or antispasmodic agents and can provide abdominal pain relief and improve the overall symptoms.


    13. Selective serotonin reuptake inhibitors may be considered to improve the sense of well-being of patients with irritable bowel syndrome.2B


    Use of invalidated diagnostic or therapeutic approaches and good access to treatment may explain the high socioeconomic burden of IBS in Korea. Therefore, organized medical guidelines on IBS based on systematic reviews of the medical literature are needed.


    For more details click on the link: https://doi.org/10.5056/jnm17145
    diarrheafiber supplementsIBSIrritable Bowel SyndromeKorean Society of Neurogastroenterology and Motilitymagnesium hydroxidemethylcellulosemonosaccharidespolyethylene glycolpolyols dietQuality of liferectal bleedingsorbitol

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok